

Eliezer Masliah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3409363/publications.pdf>

Version: 2024-02-01

116
papers

25,167
citations

34076

52
h-index

20343

116
g-index

121
all docs

121
docs citations

121
times ranked

27665
citing authors

#	ARTICLE	IF	CITATIONS
1	Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. <i>Experimental and Molecular Medicine</i> , 2022, 54, 447-454.	3.2	19
2	NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. <i>Molecular Psychiatry</i> , 2021, 26, 5751-5765.	4.1	43
3	Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer's disease. <i>Science</i> , 2021, 371, .	6.0	47
4	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2021, 80, 102-111.	0.9	35
5	Effects of innate immune receptor stimulation on extracellular β -synuclein uptake and degradation by brain resident cells. <i>Experimental and Molecular Medicine</i> , 2021, 53, 281-290.	3.2	21
6	NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease. <i>Brain</i> , 2021, 144, 3692-3709.	3.7	8
7	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	49
8	Cellular senescence and Alzheimer disease: the egg and the chicken scenario. <i>Nature Reviews Neuroscience</i> , 2020, 21, 433-444.	4.9	132
9	The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies. <i>Neurotherapeutics</i> , 2020, 17, 1061-1074.	2.1	17
10	Effects of single and combined immunotherapy approach targeting amyloid β protein and β -synuclein in a dementia with Lewy bodies-like model. <i>Alzheimer's and Dementia</i> , 2019, 15, 1133-1148.	0.4	18
11	Preclinical development of a high affinity β -synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular β -synuclein and attenuate β -synuclein spreading in vivo. <i>Neurobiology of Disease</i> , 2019, 132, 104582.	2.1	68
12	Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO- β -synuclein-A53T mouse model, correlating with increased nitration and aggregation of β -synuclein and exacerbation of motor impairment. <i>Free Radical Biology and Medicine</i> , 2019, 141, 115-140.	1.3	34
13	Systemic peptide mediated delivery of an siRNA targeting β -syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. <i>Neurobiology of Disease</i> , 2019, 127, 163-177.	2.1	30
14	NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model. <i>Neurobiology of Disease</i> , 2019, 127, 390-397.	2.1	8
15	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
16	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , 2019, 9, 561.	1.6	42
17	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
18	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13

#	ARTICLE	IF	CITATIONS
19	Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies. <i>Experimental Neurobiology</i> , 2019, 28, 547-553.	0.7	24
20	Doublecortin expression in CD8+ T cells and microglia at sites of amyloid β plaques: A potential role in shaping plaque pathology?. <i>Alzheimer's and Dementia</i> , 2018, 14, 1022-1037.	0.4	36
21	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
22	SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. <i>Journal of Neuroscience</i> , 2018, 38, 3680-3688.	1.7	98
23	The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 16165.	1.6	105
24	A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder. <i>Neurocase</i> , 2018, 24, 213-219.	0.2	12
25	Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating β -synuclein transmission and neuroinflammation. <i>Molecular Neurodegeneration</i> , 2018, 13, 43.	4.4	117
26	LRRK2 kinase regulates β -synuclein propagation via RAB35 phosphorylation. <i>Nature Communications</i> , 2018, 9, 3465.	5.8	121
27	Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 183-185.	0.4	12
28	Differential effects of immunotherapy with antibodies targeting β -synuclein oligomers and fibrils in a transgenic model of synucleinopathy. <i>Neurobiology of Disease</i> , 2017, 104, 85-96.	2.1	72
29	Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. <i>Neurobiology of Disease</i> , 2017, 106, 222-234.	2.1	48
30	MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. <i>Neurobiology of Aging</i> , 2017, 59, 156-170.	1.5	8
31	Increased BACE1 activity inhibits peripheral nerve regeneration after injury. <i>Neurobiology of Disease</i> , 2017, 106, 147-157.	2.1	16
32	SORLA attenuates EphA4 signaling and amyloid β -induced neurodegeneration. <i>Journal of Experimental Medicine</i> , 2017, 214, 3669-3685.	4.2	35
33	NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. <i>Nature Communications</i> , 2017, 8, 1488.	5.8	74
34	ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating β -secretase activity. <i>Nature Communications</i> , 2017, 8, 1472.	5.8	50
35	PPAR γ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	54
36	Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies. <i>Neural Plasticity</i> , 2017, 2017, 1-15.	1.0	29

#	ARTICLE	IF	CITATIONS
37	Non-cell-autonomous Neurotoxicity of α -synuclein Through Microglial Toll-like Receptor 2. <i>Experimental Neurobiology</i> , 2016, 25, 113-119.	0.7	77
38	Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. <i>Cell Death and Disease</i> , 2016, 7, e2499-e2499.	2.7	71
39	Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 663-672.	0.9	57
40	Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 63-72.	1.2	255
41	Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults. <i>Journal of NeuroVirology</i> , 2016, 22, 650-660.	1.0	9
42	A <i>de novo</i> compound targeting α -synuclein improves deficits in models of Parkinson's disease. <i>Brain</i> , 2016, 139, 3217-3236.	3.7	122
43	Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7564-E7571.	3.3	32
44	Five and four dimensional experiments for robust backbone resonance assignment of large intrinsically disordered proteins: application to Tau3x protein. <i>Journal of Biomolecular NMR</i> , 2016, 65, 193-203.	1.6	9
45	Exposure to bacterial endotoxin generates a distinct strain of α -synuclein fibril. <i>Scientific Reports</i> , 2016, 6, 30891.	1.6	113
46	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. <i>EMBO Reports</i> , 2016, 17, 530-551.	2.0	103
47	Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. <i>Alzheimer's and Dementia</i> , 2016, 12, 633-644.	0.4	184
48	α -Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. <i>Human Molecular Genetics</i> , 2016, 25, 1100-1115.	1.4	45
49	Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. <i>Journal of NeuroVirology</i> , 2016, 22, 366-375.	1.0	101
50	Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2016, 291, 1905-1920.	1.6	48
51	Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α -synuclein transgenic rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2016, 85, 206-217.	2.1	77
52	Differential Effects of Pharmacologic and Genetic Modulation of NMDA Receptor Activity on HIV/gp120-Induced Neuronal Damage in an In Vivo Mouse Model. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 59-65.	1.1	12
53	An Anti- β -Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. <i>PLoS ONE</i> , 2016, 11, e0152471.	1.1	33
54	Hypoxia reduces neuroinflammation and α -synuclein accumulation in a mouse model of Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2015, 12, 236.	3.1	29

#	ARTICLE	IF	CITATIONS
55	Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 669-680.	1.5	22
56	Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders. <i>Current HIV Research</i> , 2015, 13, 43-54.	0.2	48
57	Aggregates feel the strain. <i>Nature</i> , 2015, 522, 296-297.	13.7	12
58	Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice. <i>Journal of Neuroscience</i> , 2015, 35, 2358-2371.	1.7	157
59	Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. <i>Nature Neuroscience</i> , 2015, 18, 423-434.	7.1	221
60	Parkinson's Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α -Synuclein. <i>Neuron</i> , 2015, 85, 76-87.	3.8	149
61	Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats. <i>FASEB Journal</i> , 2015, 29, 911-919.	0.2	12
62	Protection from cyanide-induced brain injury by the Nrf2 transcriptional activator carnosic acid. <i>Journal of Neurochemistry</i> , 2015, 133, 898-908.	2.1	45
63	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. <i>Neuropsychologia</i> , 2015, 75, 548-555.	0.7	8
64	Parkinson Disease Mutant E46K Enhances α -Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo. <i>Journal of Biological Chemistry</i> , 2015, 290, 9412-9427.	1.6	52
65	Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. <i>Nature Medicine</i> , 2015, 21, 1154-1162.	15.2	398
66	Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. <i>Cell Reports</i> , 2015, 13, 771-782.	2.9	113
67	Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism. <i>Stem Cell Reports</i> , 2015, 5, 791-804.	2.3	58
68	Nerve Growth Factor Gene Therapy. <i>JAMA Neurology</i> , 2015, 72, 1139.	4.5	240
69	DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. <i>Nature Communications</i> , 2015, 6, 8897.	5.8	143
70	Novel therapeutic strategy for neurodegeneration by blocking $A\beta$ seeding mediated aggregation in models of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2015, 74, 144-157.	2.1	26
71	Increased Tau Phosphorylation and Aggregation in the Hippocampus of Mice Overexpressing Corticotropin-Releasing Factor. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 967-976.	1.2	40
72	ESCRT-mediated Uptake and Degradation of Brain-targeted α -synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo. <i>Molecular Therapy</i> , 2014, 22, 1753-1767.	3.7	80

#	ARTICLE	IF	CITATIONS
73	Structural Diversity of Alzheimer's Disease Amyloid- β Dimers and Their Role in Oligomerization and Fibril Formation. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 583-600.	1.2	26
74	Apathy and APOE4 are associated with Reduced BDNF Levels in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1347-1355.	1.2	55
75	Prodegenerative β -Syn expression in oligodendroglial β -synuclein models of multiple system atrophy. <i>Neurobiology of Disease</i> , 2014, 63, 171-183.	2.1	10
76	β -Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. <i>Neurobiology of Aging</i> , 2014, 35, 2357-2368.	1.5	62
77	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <i>Biochemical Pharmacology</i> , 2014, 88, 508-516.	2.0	196
78	Neurogranin binds β -synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease. <i>Brain Research</i> , 2014, 1591, 102-110.	1.1	20
79	Transglutaminase 2 exacerbates β -synuclein toxicity in mice and yeast. <i>FASEB Journal</i> , 2014, 28, 4280-4291.	0.2	29
80	Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. <i>Molecular and Cellular Neurosciences</i> , 2014, 62, 68-78.	1.0	40
81	Glucocerebrosidase depletion enhances cell-to-cell transmission of β -synuclein. <i>Nature Communications</i> , 2014, 5, 4755.	5.8	157
82	Toward a unified therapeutics approach targeting putative amyloid- β oligomer receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13680-13681.	3.3	18
83	Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models. <i>Journal of Neuroscience</i> , 2014, 34, 9441-9454.	1.7	258
84	Immunotherapy for neurodegenerative diseases: Focus on β -synucleinopathies. , 2013, 138, 311-322.		115
85	Neuron-released oligomeric β -synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. <i>Nature Communications</i> , 2013, 4, 1562.	5.8	634
86	Prion infection promotes extensive accumulation of β -synuclein in aged human β -synuclein transgenic mice. <i>Prion</i> , 2012, 6, 184-190.	0.9	24
87	Role of β -Synuclein in Adult Neurogenesis and Neuronal Maturation in the Dentate Gyrus. <i>Journal of Neuroscience</i> , 2012, 32, 16906-16916.	1.7	99
88	Antibody-Aided Clearance of Extracellular β -Synuclein Prevents Cell-to-Cell Aggregate Transmission. <i>Journal of Neuroscience</i> , 2012, 32, 13454-13469.	1.7	290
89	Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. <i>Experimental Neurology</i> , 2012, 237, 318-334.	2.0	194
90	Direct Transfer of β -Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies. <i>Journal of Biological Chemistry</i> , 2010, 285, 9262-9272.	1.6	704

#	ARTICLE	IF	CITATIONS
91	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of $\hat{\pm}$ -synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13010-13015.	3.3	1,308
92	Mutant $\hat{\pm}$ -synuclein exacerbates age-related decrease of neurogenesis. Neurobiology of Aging, 2008, 29, 913-925.	1.5	106
93	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science, 2006, 314, 130-133.	6.0	5,422
94	Transgenic Models of $\hat{\pm}$ -Synuclein Pathology. Annals of the New York Academy of Sciences, 2003, 991, 171-188.	1.8	99
95	Locally reduced levels of acidic FGF lead to decreased expression of 28-kDa calbindin and contribute to the selective vulnerability of the neurons in the entorhinal cortex in Alzheimer's disease. Neuropathology, 2001, 21, 203-211.	0.7	28
96	Altered expression of glutamate transporters under hypoxic conditions in vitro. Journal of Neuroscience Research, 2001, 64, 193-202.	1.3	17
97	Partial caudal duplication in a newborn associated with meningomyelocele and complex heart anomaly. Teratology, 2001, 63, 94-99.	1.7	25
98	TGF- $\hat{1}^2$ promotes microglial amyloid- $\hat{1}^2$ clearance and reduces plaque burden in transgenic mice. Nature Medicine, 2001, 7, 612-618.	15.2	575
99	Fibroblast growth factor modulates HIV coreceptor CXCR4 expression by neural cells. , 2000, 59, 671-679.		54
100	LDL receptor-related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis. Microscopy Research and Technique, 2000, 50, 268-272.	1.2	39
101	Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. European Journal of Neuroscience, 2000, 12, 4541-4546.	1.2	35
102	Fetal Obstructive Uropathy: Patterns of Renal Pathology. Pediatric and Developmental Pathology, 2000, 3, 223-231.	0.5	40
103	The Role of Synaptic Proteins in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 924, 68-75.	1.8	36
104	In Reply. Archives of Pathology and Laboratory Medicine, 2000, 124, 801-802.	1.2	2
105	Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease. Brain Pathology, 1999, 9, 707-720.	2.1	217
106	Abnormalities in Central Nervous System Development in Osteogenesis Imperfecta Type II. Pediatric and Developmental Pathology, 1999, 2, 124-130.	0.5	21
107	Complex Vascular Lesions at Autopsy in a Patient With Phentermine-Fenfluramine Use and Rapidly Progressing Pulmonary Hypertension. Archives of Pathology and Laboratory Medicine, 1999, 123, 539-540.	1.2	15
108	Caspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1041-1052.	0.9	134

#	ARTICLE	IF	CITATIONS
109	Amyloidogenic role of cytokine TGF- β 1 in transgenic mice and in Alzheimer's disease. <i>Nature</i> , 1997, 389, 603-606.	13.7	408
110	Genetic evidence for the involvement of ? in progressive supranuclear palsy. <i>Annals of Neurology</i> , 1997, 41, 277-281.	2.8	433
111	Glycogen synthase kinase 3 alteration in alzheimer disease is related to neurofibrillary tangle formation. <i>Molecular and Chemical Neuropathology</i> , 1996, 29, 253-261.	1.0	70
112	Differential Vulnerability of Calbindin-immunoreactive Neurons in HIV Encephalitis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 350-357.	0.9	53
113	Patterns of Neurodegeneration in HIV Encephalitis. <i>Journal of Neuro-AIDS</i> , 1995, 1, 161-173.	0.2	41
114	Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus. <i>Acta Neuropathologica</i> , 1994, 87, 135-142.	3.9	3
115	The Role of Synaptic Proteins in the Pathogenesis of Disorders of the Central Nervous System. <i>Brain Pathology</i> , 1993, 3, 77-85.	2.1	133
116	Spectrum of human immunodeficiency virus-associated neocortical damage. <i>Annals of Neurology</i> , 1992, 32, 321-329.	2.8	365